HRP20191883T1 - Modulacija ekspresije tmprss6 - Google Patents
Modulacija ekspresije tmprss6 Download PDFInfo
- Publication number
- HRP20191883T1 HRP20191883T1 HRP20191883TT HRP20191883T HRP20191883T1 HR P20191883 T1 HRP20191883 T1 HR P20191883T1 HR P20191883T T HRP20191883T T HR P20191883TT HR P20191883 T HRP20191883 T HR P20191883T HR P20191883 T1 HRP20191883 T1 HR P20191883T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- modified
- wing
- seq
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 239000002777 nucleoside Substances 0.000 claims 11
- 108091034117 Oligonucleotide Proteins 0.000 claims 8
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 5
- 125000003835 nucleoside group Chemical group 0.000 claims 5
- 101000798696 Homo sapiens Transmembrane protease serine 6 Proteins 0.000 claims 4
- 102100032452 Transmembrane protease serine 6 Human genes 0.000 claims 4
- 230000012953 feeding on blood of other organism Effects 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 229940126836 transmembrane protease serine 6 synthesis reducer Drugs 0.000 claims 4
- 230000000692 anti-sense effect Effects 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 102000018511 hepcidin Human genes 0.000 claims 2
- 229940066919 hepcidin Drugs 0.000 claims 2
- 108060003558 hepcidin Proteins 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- -1 2'-MOE nucleoside Chemical class 0.000 claims 1
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108020003589 5' Untranslated Regions Proteins 0.000 claims 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 claims 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 claims 1
- AWHIMFSHNAAMBM-GOSISDBHSA-N chembl487465 Chemical compound COCCOCCOCCOC1=CC=CC(C=2SC[C@@](C)(N=2)C(O)=O)=C1O AWHIMFSHNAAMBM-GOSISDBHSA-N 0.000 claims 1
- BOFQWVMAQOTZIW-UHFFFAOYSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N1C(C=2C(=CC=CC=2)O)=NC(C=2C(=CC=CC=2)O)=N1 BOFQWVMAQOTZIW-UHFFFAOYSA-N 0.000 claims 1
- 229940099217 desferal Drugs 0.000 claims 1
- 229940024583 exjade Drugs 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 230000014621 translational initiation Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Claims (14)
1. Antisens spoja koji obuhvaća jednolančani modificirani oligonukleotid koji se sastoji od 12-30 povezanih nukleozida, pri čemu modificirani oligonukleotid ima nukleobaznu sekvencu koja je bar 95% komplementarna sa nukleinskom kiselinom TMPRSS6, i gdje spoj snižava ekspresiju TMPRSS6, za upotrebu u liječenju talasemije kod subjekta.
2. Spoj za upotrebu prema zahtjevu 1, gdje upotreba spoja smanjuje nakupljanje željeza, povećava razine ekspresije hepcidina, i/ili smanjuje postotak zasićenja transferinom kod subjekta.
3. Spoj za upotrebu prema zahtjevu 1 ili zahtjevu 2, gdje upotreba obuhvaća terapiju flebotomijom.
4. Spoj za upotrebu prema zahtjevu 3, gdje modificirani oligonukleotid:
(i) se unosi prije terapije flebotomijom;
(i) se unosi tijekom terapije flebotomijom; ili
(i) se unosi poslije terapije flebotomijom.
5. Spoj za upotrebu prema bilo kojem prethodnom zahtjevu, gdje je modificirani oligonukleotid komplementaran sa 3’ UTR, 5’ UTR, egzonom, intronom, egzon/intron spojem, kodirajućom regijom, regijom inicijacije translacije, ili regijom završetka translacije.
6. Spoj za upotrebu prema bilo kojem prethodnom zahtjevu, gdje modificirani oligonukleotid:
(i) ima nukleobaznu sekvencu koja je bar 95%, bar 99%, ili 100% komplementarna sa nukleinskom kiselinom za TMPRSS6; i/ili
(ii) obuhvaća bar jednu modificiranu internukleozidnu vezu, opcionalno gdje je internukleozidna veza fosforotioatna internukleozidna veza; i/ili
(iii) obuhvaća modificirani šećer, opcionalno gdje je modificirani šećer biciklični šećer; i/ili
(iv) obuhvaća modificiranu nukleobazu, opcionalno gdje je modificirana nukleobaza 5-metilcitozin; i/ili
(v) se sastoji od 15 do 30, 18 do 21, 20 do 30, 20 do 29, 20 do 28, 20 do 27, 20 do 26, 20 do 25, 20 do 24, 20 do 23, 20 do 22, 20 do 21 ili 20 povezanih nukleobaza.
7. Spoj za upotrebu prema bilo kojem prethodnom zahtjevu, gdje modificirani oligonukleotid obuhvaća:
’gap’ dio koji se sastoji od povezanih deoksinukleozida;
5’ ’wing’ dio koji se sastoji od povezanih nukleozida;
3’ ’wing’ dio koji se sastoji od povezanih nukleozida;
pri čemu se ’gap’dio nalazi između 5’ ’wing’ dijela i 3’ ’wing’ dijela i pri čemu svaki nukleozid iz svakog ’wing’segmenta obuhvaća modificirani šećer, opcionalno gdje modificirani oligonukleotid obuhvaća bar jednu fosforotioatnu internukleozidnu vezu.
8. Spoj za upotrebu prema zahtjevu 7, gdje modificirani oligonukleotid obuhvaća:
’gap’dio koji se sastoji od deset povezanih deoksinukleozida;
5’ ’wing’ dio koji se sastoji od pet povezanih nukleozida; i
3’ ’wing’ dio koji se sastoji od pet povezanih nukleozida.
9. Spoj za upotrebu prema zahtjevu 7 ili zahtjevu 8, pri čemu svaki nukleozid svakog ’wing’ dijela je 2’-modificirani nukleozid ili biciklični šećer modificiranoga nukleozida.
10. Spoj za upotrebu prema zahtjevu 9, pri čemu svaki nukleozid svakog ’wing’ dijela je 2’-MOE nukleozid.
11. Spoj za upotrebu prema bilo kojem prethodnom zahtjevu, pri čemu se antisens spoja povezao.
12. Spoj za upotrebu prema bilo kojem prethodnom zahtjevu, pri čemu se spoj istovremeno unosi sa jednim ili više drugih sredstava.
13. Spoj za upotrebu prema zahtjevu 12, pri čemu drugo sredstvo:
(a) je kelator željeza, opcionalno FBS0701 (FerroKin), Exjade, Desferal, ili Deferipron; ili
(b) je agonist hepcidina; ili
(c) je drugi antisens spoja.
14. Spoj za upotrebu prema bilo kojem prethodnom zahtjevu, pri čemu nukleinska kiselina za TMPRSS6 ima nukleobaznu sekvencu bilo koju od SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, i SEQ ID NO: 7.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161556755P | 2011-11-07 | 2011-11-07 | |
| US201261710636P | 2012-10-05 | 2012-10-05 | |
| EP12847024.2A EP2776564B1 (en) | 2011-11-07 | 2012-11-07 | Modulation of tmprss6 expression |
| PCT/US2012/063970 WO2013070786A1 (en) | 2011-11-07 | 2012-11-07 | Modulation of tmprss6 expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191883T1 true HRP20191883T1 (hr) | 2019-12-27 |
Family
ID=48290517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191883TT HRP20191883T1 (hr) | 2011-11-07 | 2019-10-16 | Modulacija ekspresije tmprss6 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US9725722B2 (hr) |
| EP (2) | EP3650544A1 (hr) |
| CY (1) | CY1122511T1 (hr) |
| ES (1) | ES2761343T3 (hr) |
| HR (1) | HRP20191883T1 (hr) |
| WO (1) | WO2013070786A1 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102481317B1 (ko) | 2011-03-29 | 2022-12-26 | 알닐람 파마슈티칼스 인코포레이티드 | Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법 |
| IL293657A (en) * | 2013-05-22 | 2022-08-01 | Alnylam Pharmaceuticals Inc | Preparations of tmprss6 irna and methods of using them |
| WO2016085852A1 (en) | 2014-11-24 | 2016-06-02 | Alnylam Pharmaceuticals, Inc. | Tmprss6 irna compositions and methods of use thereof |
| CN107429250B (zh) | 2015-04-03 | 2022-03-01 | Ionis制药公司 | 用于调节tmprss6表达的化合物和方法 |
| EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
| WO2018185240A1 (en) * | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Products and compositions |
| CA3174339A1 (en) * | 2020-04-07 | 2021-10-14 | Xin Du | Anti-tmprss6 antibodies and uses thereof |
| JP2024517686A (ja) | 2021-04-26 | 2024-04-23 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 膜貫通プロテアーゼ、セリン６（ＴＭＰＲＳＳ６）ｉＲＮＡ組成物およびその使用方法 |
| MX2023012834A (es) * | 2021-04-27 | 2023-11-08 | Silence Therapeutics Gmbh | Inhibidor de la matriptasa-2 para el tratamiento de trastornos mieloproliferativos. |
| TW202400193A (zh) | 2022-06-24 | 2024-01-01 | 丹麥商諾佛 儂迪克股份有限公司 | 抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法 |
| CN117136236B (zh) * | 2022-09-29 | 2024-03-15 | 广州必贝特医药股份有限公司 | 用于抑制TMPRSS6基因表达的siRNA或其盐、药物及其应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
| US2699809A (en) | 1952-08-29 | 1955-01-18 | Nebe Kenneth | Doorknob cushion |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| EP0673559A1 (en) | 1992-12-14 | 1995-09-27 | Honeywell Inc. | Motor system with individually controlled redundant windings |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| EP2341058A3 (en) | 1997-09-12 | 2011-11-23 | Exiqon A/S | Oligonucleotide Analogues |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| PT1178999E (pt) | 1999-05-04 | 2007-06-26 | Santaris Pharma As | Análogos de l-ribo-lna |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| JP2005504020A (ja) | 2001-07-03 | 2005-02-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | ヌクレアーゼ耐性キメラオリゴヌクレオチド |
| WO2004041889A2 (en) | 2002-11-05 | 2004-05-21 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| WO2004044136A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2’-modified nucleosides for use in gene modulation |
| JP2006507841A (ja) | 2002-11-14 | 2006-03-09 | ダーマコン， インコーポレイテッド | 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ |
| US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| ATE555118T1 (de) | 2003-08-28 | 2012-05-15 | Takeshi Imanishi | Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung |
| WO2005023835A2 (en) | 2003-09-09 | 2005-03-17 | Irm Llc | Modulators of transmembrane protease serine 6 |
| JP5379347B2 (ja) | 2003-09-18 | 2013-12-25 | アイシス ファーマシューティカルズ， インコーポレーテッド | ４’−チオヌクレオシドおよびオリゴマー化合物 |
| JP5342881B2 (ja) | 2006-01-27 | 2013-11-13 | アイシス ファーマシューティカルズ， インコーポレーテッド | ６−修飾された二環式核酸類似体 |
| AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
| US20100184643A1 (en) | 2006-08-22 | 2010-07-22 | University Of Virginia Patent Foundation | Methods and Compounds Regulating the Erythroid Response to Iron Deficiency |
| US20100190837A1 (en) | 2007-02-15 | 2010-07-29 | Isis Pharmaceuticals, Inc. | 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom |
| US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| CN101796062B (zh) | 2007-07-05 | 2014-07-30 | Isis制药公司 | 6-双取代双环核酸类似物 |
| WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
| US8530640B2 (en) | 2008-02-07 | 2013-09-10 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
| US8541387B2 (en) | 2008-05-22 | 2013-09-24 | Isis Pharmaceuticals, Inc. | Modulation of SMRT expression |
| DK2356129T3 (da) | 2008-09-24 | 2013-05-13 | Isis Pharmaceuticals Inc | Substituerede alpha-L-bicykliske nukleosider |
| AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
| AU2011203986C1 (en) | 2010-01-08 | 2015-03-05 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| KR102481317B1 (ko) | 2011-03-29 | 2022-12-26 | 알닐람 파마슈티칼스 인코포레이티드 | Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법 |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
-
2012
- 2012-11-07 ES ES12847024T patent/ES2761343T3/es active Active
- 2012-11-07 EP EP19200839.9A patent/EP3650544A1/en not_active Withdrawn
- 2012-11-07 WO PCT/US2012/063970 patent/WO2013070786A1/en active Application Filing
- 2012-11-07 EP EP12847024.2A patent/EP2776564B1/en active Active
- 2012-11-07 US US14/356,863 patent/US9725722B2/en active Active
-
2016
- 2016-11-03 US US15/343,104 patent/US9885047B2/en active Active
-
2017
- 2017-12-21 US US15/850,093 patent/US10184125B2/en active Active
-
2018
- 2018-12-07 US US16/213,242 patent/US20190338288A1/en not_active Abandoned
-
2019
- 2019-10-16 HR HRP20191883TT patent/HRP20191883T1/hr unknown
-
2020
- 2020-01-02 CY CY20201100001T patent/CY1122511T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180223289A1 (en) | 2018-08-09 |
| ES2761343T3 (es) | 2020-05-19 |
| US20170073688A1 (en) | 2017-03-16 |
| US9725722B2 (en) | 2017-08-08 |
| EP2776564A1 (en) | 2014-09-17 |
| US20190338288A1 (en) | 2019-11-07 |
| US20140309286A1 (en) | 2014-10-16 |
| WO2013070786A1 (en) | 2013-05-16 |
| US9885047B2 (en) | 2018-02-06 |
| CY1122511T1 (el) | 2021-01-27 |
| EP2776564A4 (en) | 2015-06-03 |
| US10184125B2 (en) | 2019-01-22 |
| EP3650544A1 (en) | 2020-05-13 |
| EP2776564B1 (en) | 2019-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191883T1 (hr) | Modulacija ekspresije tmprss6 | |
| HRP20210244T1 (hr) | Moduliranje eksprimiranja virusa hepatitisa b (hbv) | |
| HRP20201200T1 (hr) | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK | |
| HRP20201426T1 (hr) | Postupci i pripravci za moduliranje ekspresije apolipoproteina (a) | |
| HRP20210612T1 (hr) | Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk | |
| JP2015529635A5 (hr) | ||
| JP2015536132A5 (hr) | ||
| JP2013226147A5 (hr) | ||
| EP2495248A4 (en) | NUCLEOSIDE AND NUCLEOTIDE ARTIFICIAL BRIDGES | |
| SG171676A1 (en) | Compositions and methods for inhibiting expression of the pcsk9 gene | |
| SG170780A1 (en) | Compositions and methods for inhibiting expression of eg5 gene | |
| NZ589230A (en) | Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means | |
| JP2016116520A5 (hr) | ||
| JP2015502365A5 (hr) | ||
| JP2016530882A5 (hr) | ||
| MX2015011943A (es) | Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados. | |
| RU2016146817A (ru) | Композиции и способы модулирования экспрессии ангиопоэтин-подобного белка 3 | |
| MX350944B (es) | Modulación antisentido de la expresión de gccr. | |
| RU2012114198A (ru) | Модуляция экспрессии гентингтина | |
| FI2906696T4 (fi) | Menetelmiä c9orf72:n ilmentymisen moduloimiseksi | |
| HRP20221498T1 (hr) | Pripravci serpinc1 irnk i postupci njihove upotrebe | |
| RU2013140634A (ru) | Двухцепочечная молекула рнк и ее применение | |
| MX2010009195A (es) | Rnas ultrapequeños como antagonistas del receptor tipo toll-3. | |
| WO2008036933A3 (en) | Compositions and methods for inhibiting expression of the hamp gene | |
| JP2016513976A5 (hr) |